Purdue Drug Patent Portfolio
Purdue owns 6 orange book drugs protected by 40 US patents with Chirocaine having the least patent protection, holding only 1 patent. And Targiniq with maximum patent protection, holding 24 patents. Given below is the list of Purdue's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8242131 | Methods of treating middle-of-the-night insomnia | 20 Aug, 2029 | Active |
| US7658945 | Compositions for delivering hypnotic agents across the oral mucosa and methods of use thereof | 15 Apr, 2027 | Active |
| US7674799 | Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone | 30 Mar, 2025 | Expired |
| US7674800 | Oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone | 30 Mar, 2025 | Expired |
| US7683072 | Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone | 30 Mar, 2025 | Expired |
| US9073933 | Oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone | 30 Mar, 2025 | Expired |
| US9522919 | Oxycodone compositions | 30 Mar, 2025 | Expired |
| US7682628 | Compositions for delivering hypnotic agents across the oral mucosa and methods of use thereof | 16 Feb, 2025 | Expired |
| US8252809 | Compositions for treating insomnia | 16 Feb, 2025 | Expired |
| US7988998 | Sustained-release tramadol formulations with 24-hour efficacy | 27 Oct, 2023 | Expired |
| US8846090 | Matrix for sustained, invariant and independent release of active compounds | 04 Apr, 2023 | Expired |
| US8846091 | Matrix for sustained, invariant and independent release of active compounds | 04 Apr, 2023 | Expired |
| US9555000 | Pharmaceutical preparation containing oxycodone and naloxone | 04 Apr, 2023 | Expired |
| US9907793 | Pharmaceutical preparation containing oxycodone and naloxone | 04 Apr, 2023 | Expired |
| US8969369 | Abuse-resistant controlled-release opioid dosage form | 10 May, 2022 | Expired |
| US9056051 | Abuse-resistant controlled-release opioid dosage form | 10 May, 2022 | Expired |
| US9084729 | Abuse-resistant controlled-release opioid dosage form | 10 May, 2022 | Expired |
| US9161937 | Abuse-resistant controlled-release opioid dosage form | 10 May, 2022 | Expired |
| US9168252 | Abuse-resistant controlled-release opioid dosage form | 10 May, 2022 | Expired |
| US9283216 | Abuse-resistant controlled-release opioid dosage form | 10 May, 2022 | Expired |
| US9283221 | Abuse-resistant controlled-release opioid dosage form | 10 May, 2022 | Expired |
| US9345701 | Abuse-resistant controlled-release opioid dosage form | 10 May, 2022 | Expired |
| US9511066 | Abuse-resistant controlled-release opioid dosage form | 10 May, 2022 | Expired |
| US6589960 | Hydromorphone and hydrocodone compositions and methods for their synthesis | 09 Nov, 2020 | Expired |
| US6607748 | Cross-linked high amylose starch for use in controlled-release pharmaceutical formulations and processes for its manufacture | 29 Jun, 2020 | Expired |
| US6277384 | Opioid agonist/antagonist combinations | 22 Dec, 2018 | Expired |
| US6696066 | Opioid agonist/antagonist combinations | 22 Dec, 2018 | Expired |
| US8673355 | Opioid agonist/antagonist combinations | 22 Dec, 2018 | Expired |
| US8822487 | Opioid agonist/opioid antagonist/acetaminophen combinations | 22 Dec, 2018 | Expired |
| US9205082 | Opioid agonist/antagonist combinations | 22 Dec, 2018 | Expired |
| US9474750 | Opioid agonist/opioid antagonist/acetaminophen combinations | 22 Dec, 2018 | Expired |
| US5958452 | Extruded orally administrable opioid formulations | 04 Nov, 2014 | Expired |
| US5965161 | Extruded multi-particulates | 04 Nov, 2014 | Expired |
| US6335033 | Melt-extrusion multiparticulates | 04 Nov, 2014 | Expired |
| US6706281 | Melt-extrusion multiparticulates | 04 Nov, 2014 | Expired |
| US6743442 | Melt-extruded orally administrable opioid formulations | 04 Nov, 2014 | Expired |
| US5708011 | Use of levobupivacaine in a patient having depressed myocardial contractility | 13 Oct, 2014 | Expired |
| US5591452 | Controlled release formulation | 10 May, 2014 | Expired |
| US6254887 | Controlled release tramadol | 10 May, 2014 | Expired |
| US5508042 | Controlled release oxycodone compositions | 16 Apr, 2013 | Expired |
Latest Legal Activities on Purdue's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Purdue.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Maintenance Fee Reminder Mailed | 27 Oct, 2025 | US9907793 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 24 Sep, 2025 | US11304908 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 24 Sep, 2025 | US11304909 |
| Expire Patent | 21 Jul, 2025 | US9675610 |
| Patent eGrant Notification | 22 Apr, 2025 | US12280152 |
| Mail Patent eGrant Notification | 22 Apr, 2025 | US12280152 |
| Email Notification | 22 Apr, 2025 | US12280152 |
| Recordation of Patent Grant Mailed | 22 Apr, 2025 | US12280152 |
| Recordation of Patent eGrant | 22 Apr, 2025 | US12280152 |
| Patent Issue Date Used in PTA Calculation | 22 Apr, 2025 | US12280152 |
| Issue Notification Mailed | 02 Apr, 2025 | US12280152 |
| Email Notification | 02 Apr, 2025 | US12280152 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 20 Mar, 2025 | US9775808 |
| PG-Pub Issue Notification | 13 Mar, 2025 | US12280152 |
| Email Notification | 13 Mar, 2025 | US12280152 |
Purdue Drug Patents' Oppositions Filed in EPO
Purdue drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Sep 30, 2009, by Hexal Ag. This opposition was filed on patent number EP03720425A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP11177518A | Feb, 2018 | Zentiva, k.s. | Revoked |
| EP11177516A | Feb, 2018 | Zentiva, k.s. | Revoked |
| EP11177516A | Feb, 2018 | Teva Pharmaceutical Industries Ltd | Revoked |
| EP11177518A | Feb, 2018 | Teva Pharmaceutical Industries Ltd | Revoked |
| EP11177516A | Feb, 2018 | Intas Pharmaceuticals Ltd. | Revoked |
| EP11177518A | Feb, 2018 | Intas Pharmaceuticals Ltd. | Revoked |
| EP11177518A | Jan, 2018 | STADA Arzneimittel AG | Revoked |
| EP11177516A | Jan, 2018 | STADA Arzneimittel AG | Revoked |
| EP11177518A | Nov, 2017 | G. L. Pharma GmbH | Revoked |
| EP11177516A | Nov, 2017 | G. L. Pharma GmbH | Revoked |
| EP11177516A | Nov, 2017 | Ethypharm | Revoked |
| EP11177518A | Nov, 2017 | Ethypharm | Revoked |
| EP11177520A | Aug, 2017 | Ethypharm | Revoked |
| EP11177520A | Aug, 2017 | Intas Pharmaceuticals Ltd. | Revoked |
| EP11177520A | Aug, 2017 | Teva Pharmaceutical Industries Ltd | Revoked |
| EP11177520A | Aug, 2017 | G. L. Pharma GmbH | Revoked |
| EP11177516A | Jul, 2017 | Acino Pharma AG | Revoked |
| EP11177518A | Jul, 2017 | Acino Pharma AG | Revoked |
| EP11177520A | Jun, 2017 | STADA Arzneimittel AG | Revoked |
| EP11177516A | Jun, 2017 | KRKA, d.d., Novo mesto | Revoked |
| EP11177518A | Jun, 2017 | Krka, d.d., Novo mesto | Revoked |
| EP11177516A | May, 2017 | Glenmark Pharmaceuticals Europe Ltd | Revoked |
| EP11177518A | May, 2017 | Glenmark Pharmaceuticals Europe Ltd | Revoked |
| EP11177520A | May, 2017 | Glenmark Pharmaceuticals Europe Ltd | Revoked |
| EP11177518A | May, 2017 | Hexal AG / Sandoz International GmbH | Revoked |
| EP11177518A | May, 2017 | Develco Pharma Schweiz AG | Revoked |
| EP11177516A | May, 2017 | Develco Pharma Schweiz AG | Revoked |
| EP11177516A | May, 2017 | Hexal AG / Sandoz International GmbH | Revoked |
| EP11177520A | May, 2017 | Hexal AG / Sandoz International GmbH | Revoked |
| EP11177520A | Apr, 2017 | Acino Supply AG | Revoked |
| EP11177520A | Apr, 2017 | KRKA, d.d., Novo mesto | Revoked |
| EP11177520A | Mar, 2017 | Develco Pharma Schweiz AG | Revoked |
| EP11186168A | Oct, 2016 | James Poole Limited | Opposition rejected |
| EP03720424A | Mar, 2016 | STADA Arzneimittel AG | Revoked |
| EP03720424A | Mar, 2016 | KRKA, d.d., Novo mesto | Revoked |
| EP03720424A | Mar, 2016 | FRKelly | Revoked |
| EP03720424A | Mar, 2016 | Zentiva k.s. | Revoked |
| EP03720424A | Mar, 2016 | Develco Pharma Schweiz AG | Revoked |
| EP03720424A | Mar, 2016 | ETHYPHARM | Revoked |
| EP03720424A | Mar, 2016 | G. L. Pharma GmbH | Revoked |
| EP03720424A | Mar, 2016 | Hexal AG / Sandoz International GmbH | Revoked |
| EP03720424A | Feb, 2016 | Teva Pharmaceutical Industries Ltd | Revoked |
| EP03720424A | Feb, 2016 | Acino Pharma AG | Revoked |
| EP03720424A | Dec, 2015 | Actavis Group PTC ehf | Revoked |
| EP10011792A | Oct, 2015 | Setna, Rohan P. | Granted and Under Opposition |
| EP10011792A | Oct, 2015 | Hoffmann Eitle | Granted and Under Opposition |
| EP10011792A | Oct, 2015 | James Poole Limited | Granted and Under Opposition |
| EP10011792A | Oct, 2015 | Acino Pharma AG | Granted and Under Opposition |
| EP05730345A | Dec, 2011 | Actavis group PTC ehf | Patent maintained as amended |
| EP05730345A | Dec, 2011 | Acino Pharma AG | Patent maintained as amended |
| EP05730345A | Dec, 2011 | Elend, Almut Susanne | Patent maintained as amended |
| EP03720425A | Sep, 2009 | Hexal AG | Patent maintained as amended |
Purdue's Family Patents
Purdue drugs have patent protection in a total of 44 countries. It's US patent count contributes only to 24.4% of its total global patent coverage. 6 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Purdue Drug List
Given below is the complete list of Purdue's drugs and the patents protecting them.
1. Chirocaine
Chirocaine is protected by 1 patent, which has expired already. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5708011 | Use of levobupivacaine in a patient having depressed myocardial contractility |
13 Oct, 2014
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Chirocaine's drug page
2. Intermezzo
Intermezzo is protected by 4 patents, out of which 2 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8242131 | Methods of treating middle-of-the-night insomnia |
20 Aug, 2029
(3 years from now)
| Active |
| US7658945 | Compositions for delivering hypnotic agents across the oral mucosa and methods of use thereof |
15 Apr, 2027
(9 months from now)
| Active |
| US7682628 | Compositions for delivering hypnotic agents across the oral mucosa and methods of use thereof |
16 Feb, 2025
(1 year, 4 months ago)
| Expired |
| US8252809 | Compositions for treating insomnia |
16 Feb, 2025
(1 year, 4 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Intermezzo's drug page
3. Oxycontin
Oxycontin is protected by 4 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7674799 | Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone |
30 Mar, 2025
(1 year, 2 months ago)
| Expired |
| US7674800 | Oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone |
30 Mar, 2025
(1 year, 2 months ago)
| Expired |
| US7683072 | Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone |
30 Mar, 2025
(1 year, 2 months ago)
| Expired |
| US5508042 | Controlled release oxycodone compositions |
16 Apr, 2013
(13 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Oxycontin's drug page
4. Palladone
Palladone is protected by 6 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6589960 | Hydromorphone and hydrocodone compositions and methods for their synthesis |
09 Nov, 2020
(5 years ago)
| Expired |
| US5958452 | Extruded orally administrable opioid formulations |
04 Nov, 2014
(11 years ago)
| Expired |
| US5965161 | Extruded multi-particulates |
04 Nov, 2014
(11 years ago)
| Expired |
| US6335033 | Melt-extrusion multiparticulates |
04 Nov, 2014
(11 years ago)
| Expired |
| US6706281 | Melt-extrusion multiparticulates |
04 Nov, 2014
(11 years ago)
| Expired |
| US6743442 | Melt-extruded orally administrable opioid formulations |
04 Nov, 2014
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Palladone's drug page
5. Ryzolt
Ryzolt is protected by 4 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7988998 | Sustained-release tramadol formulations with 24-hour efficacy |
27 Oct, 2023
(2 years ago)
| Expired |
| US6607748 | Cross-linked high amylose starch for use in controlled-release pharmaceutical formulations and processes for its manufacture |
29 Jun, 2020
(5 years ago)
| Expired |
| US5591452 | Controlled release formulation |
10 May, 2014
(12 years ago)
| Expired |
| US6254887 | Controlled release tramadol |
10 May, 2014
(12 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Ryzolt's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List
6. Targiniq
Targiniq is protected by 24 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7674799 | Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone |
30 Mar, 2025
(1 year, 2 months ago)
| Expired |
| US7674800 | Oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone |
30 Mar, 2025
(1 year, 2 months ago)
| Expired |
| US7683072 | Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone |
30 Mar, 2025
(1 year, 2 months ago)
| Expired |
| US9073933 | Oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone |
30 Mar, 2025
(1 year, 2 months ago)
| Expired |
| US9522919 | Oxycodone compositions |
30 Mar, 2025
(1 year, 2 months ago)
| Expired |
| US8846090 | Matrix for sustained, invariant and independent release of active compounds |
04 Apr, 2023
(3 years ago)
| Expired |
| US8846091 | Matrix for sustained, invariant and independent release of active compounds |
04 Apr, 2023
(3 years ago)
| Expired |
| US9555000 | Pharmaceutical preparation containing oxycodone and naloxone |
04 Apr, 2023
(3 years ago)
| Expired |
| US9907793 | Pharmaceutical preparation containing oxycodone and naloxone |
04 Apr, 2023
(3 years ago)
| Expired |
| US8969369 | Abuse-resistant controlled-release opioid dosage form |
10 May, 2022
(4 years ago)
| Expired |
| US9056051 | Abuse-resistant controlled-release opioid dosage form |
10 May, 2022
(4 years ago)
| Expired |
| US9084729 | Abuse-resistant controlled-release opioid dosage form |
10 May, 2022
(4 years ago)
| Expired |
| US9161937 | Abuse-resistant controlled-release opioid dosage form |
10 May, 2022
(4 years ago)
| Expired |
| US9168252 | Abuse-resistant controlled-release opioid dosage form |
10 May, 2022
(4 years ago)
| Expired |
| US9283216 | Abuse-resistant controlled-release opioid dosage form |
10 May, 2022
(4 years ago)
| Expired |
| US9283221 | Abuse-resistant controlled-release opioid dosage form |
10 May, 2022
(4 years ago)
| Expired |
| US9345701 | Abuse-resistant controlled-release opioid dosage form |
10 May, 2022
(4 years ago)
| Expired |
| US9511066 | Abuse-resistant controlled-release opioid dosage form |
10 May, 2022
(4 years ago)
| Expired |
| US6277384 | Opioid agonist/antagonist combinations |
22 Dec, 2018
(7 years ago)
| Expired |
| US6696066 | Opioid agonist/antagonist combinations |
22 Dec, 2018
(7 years ago)
| Expired |
| US8673355 | Opioid agonist/antagonist combinations |
22 Dec, 2018
(7 years ago)
| Expired |
| US8822487 | Opioid agonist/opioid antagonist/acetaminophen combinations |
22 Dec, 2018
(7 years ago)
| Expired |
| US9205082 | Opioid agonist/antagonist combinations |
22 Dec, 2018
(7 years ago)
| Expired |
| US9474750 | Opioid agonist/opioid antagonist/acetaminophen combinations |
22 Dec, 2018
(7 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Targiniq's drug page